Table 3.

Univariate analysis of patients with persistent disease after neoadjuvant therapy, by adjuvant systemic therapy status.

Variable	Residual Disease, Did Not Receive Adjuvant Therapy (n=4135, 88.8%)	Residual Disease, Received Adjuvant Therapy (n=522, 11.2%)	P value
Age (years)	62.0 ± 9.5	59.5 ± 9.4	<0.001
Gender
Male	3530 (88.2%)	473 (11.8%)	0.001
Female	605 (92.5%)	49 (9.4%)
Race
Caucasian	3886 (88.7%)	497 (11.3%)	0.32
Non-Caucasian	216 (90.8%)	22 (9.2%)
Greatest circle distance (miles)	47.8 ± 149.6	38.4 ± 75.8	0.02
Proportion in community
without high school diploma
<21% no high school degree	3570 (88.4%)	470 (11.6%)	0.06
≥21% no high school degree	472 (91.1%)	46 (8.9%)
Income
≥$38,000	3458 (88.3%)	457 (11.7%)	0.07
<$38,000	581 (90.8%)	59 (9.2%)
Population type
<250,000	2667 (88.2%)	1296 (89.5%)	0.20
≥250,000	357 (11.8%)	152 (10.5%)
Insurance Status
No private insurance	2036 (91.2%)	196 (8.8%)	<0.001
Private insurance	2065 (86.6%)	320 (13.4%)
Charlson/Deyo Score
0	3095 (88.4%)	408 (11.6%)	0.18
1	864 (90.5%)	91 (9.5%)
≥2	176 (88.4%)	23 (11.6%)
Facility Type
Academic	2173 (88.5%)	282 (11.5%)	0.53
Community	1953 (89.1%)	239 (10.9%)
Histology
Adenocarcinoma	3129 (88.5%)	405 (11.5%)	<0.001
Squamous Cell	635 (93.1%)	47 (6.9%)
Neoadjuvant type
Chemotherapy	551 (75.9%)	175 (24.1%)	<0.001
Chemoradiation therapy	3584 (91.2%)	347 (8.8%)
Path T
T0, Tis, T1	1083 (91.5%)	100 (8.5%)	<0.001
T2	1040 (90.9%)	104 (9.1%)
T3	1940 (86.1%)	314 (13.9%)
T4	71 (95.9%)	3 (4.1%)
Path N
N0	2214 (93.3%)	159 (6.7%)	<0.001
N1	1507 (84.9%)	267 (15.1%)
N2	258 (81.9%)	57 (18.1%)
N3	76 (68.5%)	35 (31.5%)
Positive Margins (≥R1)	317 (7.8%)	57 (11.2%)	0.009
Tumor size (mm)	42.8 ± 46.4	43.1 ± 22.8	0.87
Number of nodes examined	13.4 ± 9.5	15.7 ± 10.1	<0.001
Number of positive nodes	1.36 ± 2.66	2.64 ± 3.83	<0.001
Inpatient Length of Stay (days)	13.0 ± 11.4	10.9 ± 7.5	<0.001
30-day readmission	260 (6.5%)	26 (5.2%)	0.24